Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCA Model for Postinflammatory Hyperpigmentation Part II
NCT02905903Completed
- Sponsor
- Henry Ford Health
- Start
- Feb 2016
- Primary completion
- May 2018
- Countries
- 1
01
Overview
Open-label, single-arm trial, sponsored by Henry Ford Health. Primary endpoints: Optimal TCA concentration for induction of post-inflammatory hyperpigmentation at 35 days, Study genetic components of post-inflammatory hyperpigmentation by evaluating single nucleotide polymorphism and microRNA at 35 days and 1 more. Started Feb 2016; status: completed.
Beyond the preview
Go deeper on NCT02905903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02905903.